Medical Condition News

RSS

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

In an unprecedented move, chronic fatigue syndrome patients published a half-page ad in The Washington Post today. The ad brings attention to new, HIV-like retroviruses, including XMRV, which have been linked to CFS and aggressive prostate cancer, and have been detected in healthy blood donors.

6 Dec 2010

Alexithymia associated with insecure attachment styles, emotional trauma: Research

Alexithymia is inversely related to mentalization and is associated with insecure attachment styles and emotional trauma, which influence the capacity to regulate affects induced by stressful events. Alexithymia and intrapsychic conflicts may both contribute to the pathogenesis of panic attacks.

6 Dec 2010

Performance of Myconostica's MycAssay Aspergillus in CF reported at British Thoracic Society meeting

At the prestigious annual British Thoracic Society meeting in London on December 1st, Dr Caroline Baxter reported the highly sensitive performance of Myconostica's real-time PCR assay MycAssayTM Aspergillus in cystic fibrosis sputum which is 260% more sensitive than the currently used culture.

6 Dec 2010

$Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL$

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Allos Therapeutics, Inc. today reported new analysis of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Risk of heart attack increases soon after RA diagnosis: Research

The risk of having a heart attack is 60 per cent higher just a year after a patient has been diagnosed with rheumatoid arthritis, according to research published in the December issue of the Journal of Internal Medicine.

6 Dec 2010

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.

6 Dec 2010

$Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH$

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from a fully enrolled and ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with resistant and refractory chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.

6 Dec 2010

Study confirms importance of EEG as diagnostic tool in ICU

Bleeding in and around the brain (cerebral hemorrhage, including intra-cerebral hemorrhage, subdural hematoma, subarachnoid hemorrhage among other forms), from whatever cause (stroke, ruptured aneurysm, stroke, tumor, trauma, etc) can be very irritating to the electrical cells of the brain and affect how these cells transmit signals. If cells become very irritated and/or hyperactive, seizures can occur.

6 Dec 2010

Genentech announces Phase II study results of RG1678 for treatment of schizophrenia

Genentech, Inc., a member of the Roche Group, today announced eight-week results from a Phase II study of RG1678, its investigational first-in-class glycine reuptake inhibitor for the treatment of schizophrenia.

6 Dec 2010

New research focusing on VTE presented at ASH Annual Meeting

The latest advances in the treatment of bleeding and clotting disorders will be presented today at the 52nd Annual Meeting of the American Society of Hematology, focusing on venous thrombeombolism, a potentially life-threatening disorder in which abnormal blood clots form in the veins and restrict the flow of blood. New studies examine risk-prediction models and cutting-edge treatment options for patients with VTE.

6 Dec 2010

Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma

Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein inhibitor, ARRY-520. The data, which were presented at the 2010 Annual Meeting of the American Society of Hematology in Orlando, Florida, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.

6 Dec 2010

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia, and how a new gene target functions for several myeloid malignancies.

6 Dec 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

6 Dec 2010

Incidence of EPTS in children with TBI more than twice the rate in adults: Study

In the first study to utilize continuous EEG monitoring to define the incidence of early post traumatic seizures in children compared to published rates in adults, investigators at the University of Colorado followed pediatric patients with moderate to severe traumatic brain injury admitted to Denver Children's Hospital over a nine month period.

6 Dec 2010

First patient dosed with rFVIIIFc in A-LONG trial

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.

6 Dec 2010

Amgen announces final study results of Nplate in adults with chronic ITP

Amgen Inc. today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.

6 Dec 2010

Research highlighting treatment for pediatric SCD, malaria presented at ASH 2010

Red blood cells have the very important role of carrying oxygen from the lungs to the rest of the body; therefore, disorders that affect RBCs can have a significant impact on quality of life. Sickle cell disease and malaria are two common RBC diseases that affect a significant portion of the U.S. and global populations. Sickle cell disease, a genetic blood disorder that causes deformed and dysfunctional red blood cells, affects an estimated 70,000 to 100,000 Americans, while malaria affects approximately 1,500 Americans annually and 190 to 311 million people worldwide.

6 Dec 2010

Cell Therapeutics announces new pixantrone EOS follow up results

Cell Therapeutics, Inc. today announced new pixantrone end of study follow up results from the Company's pivotal phase III PIX301 trial, which results form the basis for the Company's recent Marketing Authorization Application currently under review by the European Medicines Agency.

6 Dec 2010

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Genentech, Inc., a member of the Roche Group, and Biogen Idec announced today positive data from a Phase III study of Rituxan (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease).

6 Dec 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.

6 Dec 2010

Medical Condition News

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

Alexithymia associated with insecure attachment styles, emotional trauma: Research

Performance of Myconostica's MycAssay Aspergillus in CF reported at British Thoracic Society meeting

Allos Therapeutics reports new analysis of PROPEL trial data of FOLOTYN in patients with refractory PTCL

Risk of heart attack increases soon after RA diagnosis: Research

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Study confirms importance of EEG as diagnostic tool in ICU

Genentech announces Phase II study results of RG1678 for treatment of schizophrenia

New research focusing on VTE presented at ASH Annual Meeting

Phase 1 clinical data: ARRY-520 shows positive preliminary results in treating multiple myeloma

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Incidence of EPTS in children with TBI more than twice the rate in adults: Study

First patient dosed with rFVIIIFc in A-LONG trial

Amgen announces final study results of Nplate in adults with chronic ITP

Research highlighting treatment for pediatric SCD, malaria presented at ASH 2010

Cell Therapeutics announces new pixantrone EOS follow up results

Genentech, Biogen report Phase III study data of Rituxan in patients with advanced follicular lymphoma

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News